01—Abstract
Summary
Summary of the 8-K filed January 30, 2025. Cited figures are marked; the original filing is the authoritative source.
Thermo Fisher Scientific (TMO) reported fourth quarter and full year 2024 results on January 30, 2025, showing a strong close to the year but flat annual performance.
Q4 revenue grew 5% to $11.40 billiona, with organic revenue growth of 4% and Core organic growth of 5%. GAAP diluted EPS rose 14% to $4.78, and adjusted EPS grew 8% to $6.10, with adjusted operating margin expanding to 23.9% from 23.4%. For the full year, revenue was essentially flat at $42.88 billion, with organic and Core organic growth both at 0%.
Adjusted EPS rose 1% to $21.86b, while adjusted operating income declined to $9.71 billion from $9.81 billion and adjusted operating margin slipped to 22.6% from 22.9%. The balance sheet and capital allocation were central to the year. Thermo Fisher completed the Olink acquisition, spent $3.1 billion on acquisitions net of cash acquired, and returned $4.6 billion to shareholders through buybacks ($4.0 billion) and dividends ($583 million).
Free cash flow rose 4% to $7.32 billionc. Cash and cash equivalents fell to $4.0 billion from $8.1 billion, partly offset by $1.56 billion in short-term investments, and total debt-related obligations declined, with long-term obligations down to $29.1 billion from $31.3 billion. Management emphasized that the company exited 2024 with momentum and said it is well positioned for 2025.
Full-year 2025 guidance was not included in the release and was to be provided on the earnings call the same morning. Investors should note that the Q4 improvement reflects a sharp turn from the flat full-year trend, and that GAAP results benefited from lower amortization and restructuring-related charges that are excluded from adjusted metrics.
02—Key points
Key Highlights
- Q4 2024 revenue rose 5% to $11.40 billion; organic growth was 4% and Core organic growth was 5%.
- Q4 GAAP diluted EPS grew 14% to $4.78 and adjusted EPS grew 8% to $6.10.
- Full-year 2024 revenue was flat at $42.88 billion, with organic and Core organic growth both at 0%.
- Full-year adjusted EPS rose 1% to $21.86, while adjusted operating margin declined to 22.6% from 22.9%.
- Free cash flow increased to $7.32 billion from $7.01 billion, and the company returned $4.6 billion to shareholders.
- Completed the Olink acquisition and spent $3.1 billion on acquisitions net of cash acquired during 2024.
- 2025 financial guidance was not included in the release and was deferred to the earnings call held the same morning.
03—Questions
Frequently Asked Questions
How did Thermo Fisher perform in the fourth quarter of 2024?
Q4 2024 revenue grew 5% to $11.40 billion, with organic growth of 4% and Core organic growth of 5%. GAAP diluted EPS rose 14% to $4.78, and adjusted EPS grew 8% to $6.10. Adjusted operating margin improved to 23.9% from 23.4%.
Why was full-year 2024 performance weaker than the fourth quarter?
Full-year revenue was flat at $42.88 billion, with organic and Core organic growth at 0%. Adjusted operating income declined to $9.71 billion from $9.81 billion, and adjusted operating margin fell to 22.6% from 22.9%. The release does not attribute the weakness to specific causes, but the Q4 improvement represents a notable turnaround in momentum.
How much capital did Thermo Fisher return to shareholders and how did it deploy capital?
The company returned $4.6 billion through stock buybacks of $4.0 billion and dividends of $583 million. It also spent $3.1 billion on acquisitions net of cash acquired, including Olink, and made $3.4 billion in investment purchases, partly offset by $1.8 billion in investment sales and maturities.
What does the 2025 outlook look like?
The press release did not include 2025 guidance. Management stated it would provide 2025 financial guidance on the earnings conference call held on January 30, 2025 at 8:30 a.m. Eastern Time, and said the company is in a great position to deliver excellent performance in 2025. Investors should review the call commentary for specific targets.
Why do GAAP and adjusted EPS differ so much?
The gap largely reflects exclusions for amortization of acquisition-related intangible assets, which was $1.14 per share in Q4 and $5.09 for the full year, along with restructuring costs and other acquisition-related items. Adjusted EPS excludes these items to show core operating performance, while GAAP results include them.
04—Continue